Down-regulation of K-ras and H-ras in human brain gliomas

European Journal of Cancer

Volumn 45, Issue 7, 2009, Pages 1294-1303

  Lymbouridou, Rena ^a   Soufla, Giannoula ^a   Chatzinikola, Anthoula M ^a   Vakis, Antonios ^b   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Astrocytomas; Glioblastomas multiforme; Prognosis; Ras

Indexed keywords

PROTEIN P21;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLIOMA; HUMAN; MUTATIONAL ANALYSIS; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; ASTROCYTOMA; BLOTTING, WESTERN; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CODON; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GLIOBLASTOMA; GLIOMA; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEIN P21(RAS); POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 64049105722     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.12.028     Document Type: Article

References (40)

1. Kiaris H., and Spandidos D.A. Mutations of ras genes in human tumours (review). Int J Oncol 7 (1995) 413-421
2. Spandidos D.A., Sourvinos G., Tsatsanis C., and Zafiropoulos A. Normal ras genes: Their onco-suppressor and pro-apoptotic functions (review). Int J Oncol 21 (2002) 237-241
3. Spandidos D.A., and Wilkie N.M. Malignant transformation of early passage rodent cells by a single mutated human oncogene. Nature 310 (1984) 469-475
4. Sharma M.K., Zehnbauer B.A., Watson M.A., and Gutmann D.H. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 25 65 (2005) 1335-1336
5. Janzarik W.G., Kratz C.P., Loges N.T., et al. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics 38 (2007) 61-63
6. Spandidos D.A., Glarakis I.S., Kotsinas A., Ergazaki M., and Kiaris H. Ras oncogene activation in benign and malignant colorectal tumours. Tumouri 81 (1995) 7-11
7. Spandidos D.A., Liloglou T., Arvanitis D., and Gourtsoyiannis N.C. Ras gene activation in human small intestinal tumours. Int J Oncol 2 (1993) 513-518
8. Rodenhuis S., and Slebos R.J. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52 Suppl. (1992) 2665-2669
9. Dokianakis D.N., Sourvinos G., Sakkas S., et al. Detection of HPV and ras gene mutations in cervical smears from female genital lesions. Oncol Rep 5 (1998) 1195-1198
10. Koffa M., Malamou-Mitsi V., Agnantis N.J., and Spandidos D.A. Mutational activation of K-ras oncogene in human breast tumours. Int J Oncol 4 (1994) 573-576
11. Roth S., Partanen T., Suitiala T., et al. Molecular analysis of occupational cancer: infrequent p53 and ras mutations in renalcell cancer in workers exposed to gasoline. Int J Cancer 14 (1997) 492-496
12. Spandidos D.A., and Agnantis N.J. Human malignant tumours of the breast as compared to their normal tissue have elevated expression of the Harvey ras oncogene. Anticancer Res 4 (1984) 269-272
13. Whittaker J.L., Walker R.A., and Varley J.M. Differential expression of cellular oncogenes in benign and malignant human breast tissue. Int J Cancer 38 (1986) 651-655
14. Czerniak B., Herz F., Koss L.G., and Schlom J. ras oncogene p21 as a tumour marker in the cytodiagnosis of gastric and colonic carcinomas. Cancer 60 (1987) 2432-2436
15. De Biasi F., Del Sal G., and Horan-Hand P. Evidence of enhancement of the ras oncogene protein product (p21) in a spectrum of human cancers. Int J Cancer 43 (1989) 431-435
16. Kurzrock R., Gallick G.E., and Gutterman J.U. Differential expression of p21 ras gene products among histological subtypes of fresh primary human lung tumours. Cancer 69 (1994) 367-371
17. Barault L., Veyrie N., Jooste V., et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signalling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122 (2008) 2255-2259
18. Marks J.L., Broderick S., Zhou Q., et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3 (2008) 111-116
19. Monnat M., Tardy S., Saraga P., Diggelman H., and Costa J. Prognostic implications of expression of the cellular gene myc, fos, Ha-ras and Ki-ras in colon carcinoma. Int J Cancer 40 (1987) 293-299
20. Clair T., Miller W.R., and Cho-Chung Y.S. Prognostic significance of the expression of a ras with a molecular weight of 21,000 by human breast cancer. Cancer 47 (1987) 5290-5293
21. Maltzman T.H., Mueller B.A., Schroeder J., et al. Ras oncogene mutations in childhood brain tumours. Cancer Epidemiol Biomarkers Prev 6 (1997) 239-243
22. Sharma M.K., Zehnbauer B.A., Watson M.A., and Gutmann D.H. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytomas. Neurology 65 (2005) 1335-1336
23. Ireland C.M. Activated N-ras oncogenes in human neuroblastomas. Cancer Res 49 (1989) 5530-5533
24. Iolascon A., Lania A., Badiali M., et al. Analysis of N-ras gene mutations in medulloblastomas by polymerase chain reaction and oligonucleotide probes in formalin-fixed, paraffin-embedded tissues. Med Pediatr Oncol 19 (1991) 240-245
25. Patt S., Thiel G., Zhou Q., et al. Chromosomal changes and correspondingly altered proto-oncogene expression in human gliomas. Value of combined cytogenetic and molecular genetic analysis. Anticancer Res 13 (1993) 113-118
26. Salgaller M., Agius L., Yates A., Pearl D., Roberts W., and Stephens R. Application of automated image analysis to demonstrate the correlation between ras p21 expression and severity of gliomas. Biochem Biophys Res Commun 169 (1990) 482-491
27. Miyakis S., Sourvinos G., and Spandidos D.A. Differential expression and mutation of the ras family genes in human breast cancer. Biochem Biophys Res Commun 251 (1998) 609-612
28. MacDonald T.J., Pollack I.F., Okada H., Bhattacharya S., and Lyons-Weiler J. Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. Methods Mol Biol 377 (2007) 203-222
29. Van den Boom J., Wolter M., Kuick R., et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription polymerase chain reaction. Am J Pathol 163 3 (2003) 1033-1043
30. Rickman D.S., Bobek M.P., Misek D.E., et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 61 18 (2001) 6885-6891
31. Reddy P.S., Umesh S., Thota B., et al. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther 7 5 (2008) 663-668
32. Gerosa M.A., Talarico D., and Fognani C. Et al. Overexpression of N-ras oncogene and epidermal growth factor receptor gene in human glioblastomas. J Natl Cancer Inst 4 81 (1989) 63-67
33. Spandidos D.A., and Wilkie N.M. The normal human H-ras1 gene can act as an onco-suppressor. Brit J Cancer Suppl 9 (1988) 67-71
34. Spandidos D.A., Frame M., and Wilkie N.M. Expression of the normal H-ras1 gene can suppress the transformed and tumourigenic phenotypes induced by mutant ras genes. Anticancer Res 10 (1990) 1543-1554
35. Zhang Z., Wang Y., Vikis H.G., et al. Wild-type Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 29 (2001) 25-33
36. Wyllie A.H., Rose K.A., Morris R.G., Steel C.M., Foster E., and Spandidos D.A. Rodent fibroblast tumours expressing human myc and ras genes: growth, metastasis and endogenous oncogene expression. Brit J Cancer 56 (1987) 251-259
37. Vater C.A., Bartle L.M., Dionne C.A., Littlewood T.D., and Goldmacher V.S. Induction of apoptosis by tamoxifen-activation of a p53-estrogen receptor fusion protein expressed in E1A and T24 H-ras transformed p53-/- mouse embryo fibroblasts. Oncogene 13 (1996) 739-748
38. Trent II J.C., McConkey D.J., Loughlin S.M., Harbison M.T., Fernandez A., and Ananthaswamy H.N. Ras signaling in tumour necrosis factor-induced apoptosis. EMBO J 15 (1996) 4405-4497
39. Kauffman-Zeh A., Rodriguez-Viciana P., Ulrich E., et al. Suppression of c-Myc-induced apoptosis by Ras signaling through PI(3)K and PKB. Nature 385 (1997) 544-548
40. Zhu J., Woods D., McMahon M., and Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 12 (1998) 2997-3007